Imaging of Gastrointestinal Stromal Tumors and Assessment of Benefit from SystemicTherapy

被引：8

作者：

Boonsirikamchai, Piyaporn ^{[1
]}

Podoloff, Donald A. ^{[1
]}

Choi, Haesun ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2009年 / 23卷 / 01期

关键词：

Gastrointestinal stromal tumors; Imaging; Computed tomography; POSITRON-EMISSION-TOMOGRAPHY; IMATINIB MESYLATE; FDG-PET; RESPONSE EVALUATION; PROGNOSTIC-FACTORS; INHIBITOR STI571; CANCER-CELLS; C-KIT; THERAPY; DIAGNOSIS;

D O I：

10.1016/j.hoc.2008.12.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

While gastrointestinal stromal tumors have been increasingly recognized with the prolonged survival and highly effective new targeted treatments the role of imaging has become important not only for diagnosing and staging the tumors, but also for monitoring the effects of treatment and surveillance. Computed tomography is the imaging modality of choice for these purposes. Fluorine-18 fluorodeoxyglucose positron emission tomography is primarily used in problem solving when there are inconsistencies between CT and clinical findings or inconclusive CT images. The roles of MRI and ultrasound are also described.

引用

页码：35 / +

页数：15

共 58 条

[1]

Antoch G, 2004, J NUCL MED, V45, P357

[2] We should desist using RECIST, at least in GIST [J].

Benjamin, Robert S. ;

Choi, Haesun ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Charnsangavej, Chuslip .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1760-1764

[3]

Berger F, 2007, 93 SCI ASS ANN M RAD, P534

[4]

Blanke C, 2004, P 2004 GASTR CANC S, P43

[5] Endosonographic diagnosis of submucosal upper gastrointestinal tract lesions and large fold gastropathies by catheter ultrasound probe [J].

Buscarini, E ;

Di Stasi, M ;

Rossi, S ;

Silva, M ;

Giangregorio, F ;

Adriano, Z ;

Buscarini, L .

GASTROINTESTINAL ENDOSCOPY, 1999, 49 (02) :184-191

[6] A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors [J].

Chen, LL ;

Trent, JC ;

Wu, EF ;

Fuller, GN ;

Ramdas, L ;

Zhang, W ;

Raymond, AK ;

Prieto, VG ;

Oyedeji, CO ;

Hunt, KK ;

Pollock, RE ;

Feig, BW ;

Hayes, KJ ;

Choi, H ;

Macapinlac, HA ;

Hittelman, W ;

Velasco, MA ;

Patel, S ;

Burgess, MA ;

Benjamin, RS ;

Frazier, ML .

CANCER RESEARCH, 2004, 64 (17) :5913-5919

[7] CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings [J].

Choi, H ;

Charnsangavej, C ;

Faria, SD ;

Tamm, EP ;

Benjamin, RS ;

Johnson, MM ;

Macapinlac, HA ;

Podoloff, DA .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2004, 183 (06) :1619-1628

[8] Response evaluation of gastrointestinal stromal tumors [J].

Choi, Haesun .

ONCOLOGIST, 2008, 13 :4-7

[9] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].

Choi, Haesun ;

Charnsangavej, Chuslip ;

Faria, Silvana C. ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Benjamin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759

[10]

Delbeke D, 1999, J NUCL MED, V40, P1706

← 1 2 3 4 5 6 →